Related Experiment Videos
Combined modality therapy for cutaneous T-cell lymphoma
M Duvic1, N A Lemak, J R Redman
1Department of Medical Specialties, University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA.
Journal of the American Academy of Dermatology
|June 1, 1996
Summary
This study combined therapies for Cutaneous T-cell lymphoma (CTCL), achieving an 82% response rate. While some advanced cases had short remissions, early-stage patients showed promising long-term outcomes.
Area of Science:
- Oncology
- Dermatology
Background:
- Cutaneous T-cell lymphoma (CTCL) has limited long-term disease-free survival options.
- Advanced CTCL patients face a median survival of approximately 3 years.
Purpose of the Study:
- To sequentially combine effective agents for CTCL treatment.
- To improve remission rates and duration in CTCL patients.
Main Methods:
- Sequential therapy combining recombinant interferon alfa and isotretinoin for 4 months.
- Total skin electron beam therapy, with or without chemotherapy based on disease stage (I-IV).
- Maintenance therapy included interferon and topical nitrogen mustard.
Main Results:
- An 82% overall response rate (complete and partial remissions) was observed in 28 treated patients.
- Median remission duration was 5 months for advanced (III-IV) disease, with 2 patients in long-term remission (39+, 46+ months).
- Median remission duration not reached for early (I-II) stage disease at 18 months follow-up.
Conclusions:
- Combined modality therapy demonstrates efficacy in treating CTCL.
- Response rates are comparable to existing therapies for CTCL.